SERB Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- SERB Pharmaceuticals's estimated annual revenue is currently $88.4M per year.
- SERB Pharmaceuticals's estimated revenue per employee is $201,000
Employee Data
- SERB Pharmaceuticals has 440 Employees.
- SERB Pharmaceuticals grew their employee count by 23% last year.
SERB Pharmaceuticals's People
Name | Title | Email/Phone |
---|---|---|
1 | Director Corporate Communications and ESG | Reveal Email/Phone |
SERB Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $24.3M | 121 | 6% | N/A | N/A |
#2 | $29.9M | 149 | 10% | N/A | N/A |
#3 | $29.1M | 145 | 9% | N/A | N/A |
#4 | $44.8M | 223 | -2% | N/A | N/A |
#5 | $28.9M | 144 | -5% | N/A | N/A |
#6 | $64.7M | 322 | 10% | N/A | N/A |
#7 | $43.2M | 215 | 37% | N/A | N/A |
#8 | $64.7M | 322 | 10% | N/A | N/A |
#9 | $88.4M | 440 | 23% | N/A | N/A |
#10 | N/A | 57 | 43% | N/A | N/A |
What Is SERB Pharmaceuticals?
SERB is a growing pharmaceutical company and a dedicated ally to healthcare providers treating patients with critical conditions, focusing on emergency care and rare diseases. For over 30 years we have made treating these complex and life-threatening conditions possible; supporting clinicians, healthcare systems and governments while offering hope to patients and their families. As a fully integrated company, we have the experience and capabilities to acquire, develop, and manufacture our medicines to the highest standards, and make them available worldwide through our secure supply chain. SERB operates in the US as BTG Pharmaceuticals.
keywords:N/AN/A
Total Funding
440
Number of Employees
$88.4M
Revenue (est)
23%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $88.4M | 442 | 8% | N/A |
#2 | $162.3M | 481 | 77% | N/A |
#3 | $117.6M | 577 | 9% | N/A |
#4 | $187.6M | 591 | 12% | N/A |
#5 | $187.6M | 591 | 12% | N/A |